NASDAQ: NCELNewcelx Ltd Stock
$4.01-0.14 (-3.37%)
Updated Nov 7, 2025
NCEL Price
$4.01
Fair Value Price
N/A
Market Cap
$1.66M
52 Week Low
$3.86
52 Week High
$41.50
P/E
-0.49x
P/B
0.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.51
Operating Cash Flow
-$1M
Beta
0.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NCEL Overview
NLS Pharmaceutics AG is developing therapies for patients with rare and complex central nervous system disorders (e.g., narcolepsy, idiopathic hypersomnia, and other rare sleep disorders), as well as neurodevelopmental disorders (e.g, attention deficit hyperactivity disorder). The company's lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy, and Nolazol for the treatment of ADHD. NLS Pharmaceutics was incorporated in 2015 and is based in Zurich, Switzerland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NCEL's potential to beat the market
- NCEL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NCEL
RankedUnranked of 483
RankedUnranked of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.44 | A | |
| $105.98 | A | |
| $131.16 | A |
Be the first to know about important NCEL news, forecast changes, insider trades & much more!
NCEL News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NCEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NCEL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NCEL is good value based on its book value relative to its share price (0.58x), compared to the US Biotechnology industry average (4.86x)
P/B vs Industry Valuation
NCEL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NCEL due diligence checks available for Premium users.
Valuation
NCEL fair value
Fair Value of NCEL stock based on Discounted Cash Flow (DCF)
Price
$4.01
Fair Value
$1.08
Overvalued by
271.60%
NCEL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NCEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.49x
Industry
237.99x
Market
44.79x
NCEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
4.86x
NCEL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NCEL's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
NCEL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.3M
Liabilities
$1.5M
Debt to equity
0.51
NCEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NCEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NCEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NCEL vs Biotech Stocks
Newcelx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.